Posted by Michael Wonder on 23 Aug 2023
Comanche Biopharma receives US FDA fast track designation for CBP-4888 for the treatment of sFlt-1 mediated pre-term preeclampsia
23 August 2023 - Comanche Biopharma today announced that they have received fast track designation from the US FDA for the investigation of CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia.
CBP-4888 is a subcutaneously delivered siRNA therapeutic that is currently in a Phase 1 clinical trial.
